Patents by Inventor Taku Murakami

Taku Murakami has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220254568
    Abstract: A dielectric composition includes main-phase particles each including a main component having a perovskite crystal structure represented by a general formula of ABO3. At least a part of the main-phase particles has a core-shell structure. The dielectric composition includes RA, RB, M, and Si. Each of A, B, RA, RB, and M is one or more elements selected from a specific element group. SRA/SRB>CRA/CRB is satisfied, where CRA is an RA content (mol %) to the main component in terms of RA2O3, and CRB is an RB content (mol %) to the main component in terms of RB2O3, in the dielectric composition, and SRA is an average RA content (mol %), and SRB is an average RB content (mol %), in a shell part of the core-shell structure.
    Type: Application
    Filed: January 31, 2022
    Publication date: August 11, 2022
    Applicant: TDK CORPORATION
    Inventors: Taku MURAKAMI, Nobuto MORIGASAKI, Takuma ARIIZUMI, Toshihiko KANEKO, Yasuhiro ITO
  • Publication number: 20220254567
    Abstract: A dielectric composition includes a main-phase particle and segregation particles. The main-phase particle includes a main component having a perovskite crystal structure represented by a general formula of ABO3. The dielectric composition includes RA, RB, M, and Si. Each of A, B, RA, RB, and M is one or more elements selected from a specific element group. Each of an RA content CRA to the main component, an RB content CRB to the main component, an M content to the main component, and a Si content to the main component is within a predetermined range. 0.50<(?/?)/(CRA/CRB)?1.00 is satisfied, where a is an average RA content (mol %) and f3 is an average RB content (mol %) of specific segregation particles mainly including RA, RB, Si, Ba, and Ti in the segregation particles.
    Type: Application
    Filed: January 31, 2022
    Publication date: August 11, 2022
    Applicant: TDK CORPORATION
    Inventors: Taku MURAKAMI, Nobuto MORIGASAKI, Takuma ARIIZUMI, Toshihiko KANEKO, Yasuhiro ITO
  • Publication number: 20220254569
    Abstract: A dielectric composition includes a main phase and segregation phases each including RE (at least one rare earth element). The main phase includes a main component having a perovskite crystal structure of ABO3 (A is one or more selected from Ba, Sr, and Ca, and B is one or more selected from Ti, Zr, and Hf). The segregation phases are classified into first segregation phases whose atomic ratio of Si to RE is 0 or more and 0.20 or less and second segregation phases whose atomic ratio of Si to the RE is more than 0.20. 0?S1/S2?0.10 is satisfied on a cross section of the dielectric composition, where S1 is an area ratio of the first segregation phases, and S2 is an area ratio of the second segregation phases. An atomic ratio of Si to RE in the second segregation phases is 0.80 or less on average.
    Type: Application
    Filed: January 31, 2022
    Publication date: August 11, 2022
    Applicant: TDK CORPORATION
    Inventors: Takuma ARIIZUMI, Taku MURAKAMI, Nobuto MORIGASAKI, Toshihiko KANEKO, Yasuhiro ITO
  • Publication number: 20220254570
    Abstract: A dielectric composition includes a main phase, first segregation phases, and second segregation phases. The main phase includes a main component having a perovskite crystal structure of ABO3 (A is one or more selected from Ba, Sr, and Ca, and B is one or more selected from Ti, Zr, and Hf). The first segregation phases include RE (one or more selected from rare earth elements), A, Si, Ti, and O. The second segregation phases include RE, A, Ti, and O and do not substantially include Si. 0.10<S2/S1?1.50 is satisfied on a cross section of the dielectric composition, where S1 is an area ratio of the first segregation phases, and S2 is an area ratio of the second segregation phases.
    Type: Application
    Filed: February 1, 2022
    Publication date: August 11, 2022
    Applicant: TDK CORPORATION
    Inventors: Takuma ARIIZUMI, Taku MURAKAMI, Nobuto MORIGASAKI, Toshihiko KANEKO, Yasuhiro ITO
  • Publication number: 20210304966
    Abstract: A dielectric ceramic composition includes a barium titanate, an oxide of an R element, an oxide of an M element, and an oxide containing Si. The R element is one or more elements selected from Eu, Gd, Tb, Dy, Y, Ho, and Yb. The M element is one or more elements selected from Mg, Ca, Mn, V, and Cr. A ratio of an amount of the oxide of the R element in terms of R2O3 to an amount of the oxide containing Si in terms of SiO2 is 0.8:1 to 2.2:1. A ratio of an amount of the oxide of the M element in terms of MO to the amount of the oxide containing Si in terms of SiO2 is 0.2:1 to 1.8:1.50% or more of the number of dielectric particles constituting the dielectric ceramic composition is core-shell dielectric particles having a core-shell structure.
    Type: Application
    Filed: March 8, 2021
    Publication date: September 30, 2021
    Applicant: TDK CORPORATION
    Inventors: Taku MURAKAMI, Nobuto MORIGASAKI, Dan SAKURAI, Takuma ARIIZUMI, Toshihiko KANEKO
  • Publication number: 20210277483
    Abstract: The present disclosure relates to methods of collecting exosomes and microvesicles (EMV) from urine, isolating corresponding mRNA, and analyzing expression patterns in order to diagnose and treat various urothelial cancers. In particular, various expression patterns are analyzed through a unique diagnostic formula.
    Type: Application
    Filed: April 23, 2021
    Publication date: September 9, 2021
    Inventors: Taku Murakami, Cindy M. Yamamoto, Masato Mitsuhashi, Hiroshi Harada
  • Patent number: 11028443
    Abstract: The present disclosure relates to methods of collecting exosomes and microvesicles (EMV) from urine, isolating corresponding mRNA, and analyzing expression patterns in order to diagnose and treat various urothelial cancers. In particular, various expression patterns are analyzed through a unique diagnostic formula.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: June 8, 2021
    Assignees: Showa Denko Materials Co., Ltd., Showa Denko Materials (America), Inc., City of Sapporo
    Inventors: Taku Murakami, Cindy M. Yamamoto, Masato Mitsuhashi, Hiroshi Harada
  • Patent number: 10697001
    Abstract: Provided herein are devices and methods for the capture or isolation of a biomarker from a biological sample. In several embodiments, the device comprises a loading region, a filter material, and a receiving region. In particular, in several embodiments, biological fluid is passed from the loading region through the filter material and into the receiving region, thereby resulting in capture or isolation of a biomarker.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: June 30, 2020
    Assignees: HITACHI CHEMICAL CO., LTD., HITACHI CHEMICAL CO. AMERICA, LTD.
    Inventors: Masato Mitsuhashi, Taku Murakami
  • Patent number: 10542745
    Abstract: Disclosed are methods, device kits, and systems for improved quantification of mRNA from whole blood. More particularly, the devices and kites related thereto are useful for the controlled and repeatable ex vivo stimulation of whole blood.
    Type: Grant
    Filed: October 31, 2011
    Date of Patent: January 28, 2020
    Assignees: Hitachi Chemical Co., Ltd., Hitachi Chemical Company America, Ltd.
    Inventors: Masato Mitsuhashi, Taku Murakami
  • Patent number: 10470262
    Abstract: The invention is to provide an electrical circuit and a control method remotely controlling LED brightness adjustment and color temperature adjustment, and the electrical circuit includes a voltage stabilizing circuit, a microprocessor MCU, a receiving module, an LED constant current driving circuit, an LED light adjustment and color temperature adjustment separation circuit, a bicolor temperature LED light source and system processing software.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: November 5, 2019
    Inventors: Osamu Murakami, Toshio Murakami, Taku Murakami
  • Patent number: 10370719
    Abstract: The present disclosure relates to methods of collecting exosomes and microvesicles (EMV) from urine and isolating corresponding mRNA in order to diagnose and treat acute kidney injury (AKI). In particular, certain embodiments relate to the method of capturing EMV from urine applied to a filter device that is capable of capturing EMV. Nucleic acids such as mRNA can be isolated from the EMV using an oligo(dT)-coated plate designed to accommodate the filter device and then used for further molecular analysis. Quantification of the collected nucleic acids may then be used in the diagnosis and/or treatment of IBD.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: August 6, 2019
    Assignees: Hitachi Chemical Co., Ltd., Hitachi Chemical Co. America, Ltd., The Regents of the University of California
    Inventors: Satish P. RamachandraRao, Ravindra Lall Mehta, Masato Mitsuhashi, Taku Murakami
  • Publication number: 20190230760
    Abstract: The invention is to provide an electrical circuit and a control method remotely controlling LED brightness adjustment and color temperature adjustment, and the electrical circuit includes a voltage stabilizing circuit, a microprocessor MCU, a receiving module, an LED constant current driving circuit, an LED light adjustment and color temperature adjustment separation circuit, a bicolor temperature LED light source and system processing software.
    Type: Application
    Filed: January 22, 2019
    Publication date: July 25, 2019
    Inventors: Osamu MURAKAMI, Toshio MURAKAMI, Taku MURAKAMI
  • Publication number: 20180327852
    Abstract: The present disclosure relates to methods of collecting exosomes and microvesicles (EMV) from urine, isolating corresponding mRNA, and analyzing expression patterns in order to diagnose and treat various urothelial cancers. In particular, various expression patterns are analyzed through a unique diagnostic formula.
    Type: Application
    Filed: August 30, 2016
    Publication date: November 15, 2018
    Inventors: Taku Murakami, Cindy M. Yamamoto, Masato Mitsuhashi, Hiroshi Harada
  • Publication number: 20180265914
    Abstract: The present disclosure relates to methods of collecting exosomes and microvesicles (EMV) from urine, isolating corresponding mRNA, and analyzing expression patterns in order to diagnose and treat various post-kidney transplant complications. In particular, annexin1 mRNA expression patterns are analyzed through a unique diagnostic formula.
    Type: Application
    Filed: August 30, 2016
    Publication date: September 20, 2018
    Inventors: Taku Murakami, Cindy M. Yamamoto, Masato Mitsuhashi, Hiroshi Harada
  • Publication number: 20170335397
    Abstract: The present disclosure relates to methods of collecting exosomes and microvesicles (EMV) from urine and isolating corresponding mRNA in order to diagnose and treat acute kidney injury (AKI). In particular, certain embodiments relate to the method of capturing EMV from urine applied to a filter device that is capable of capturing EMV. Nucleic acids such as mRNA can be isolated from the EMV using an oligo(dT)-coated plate designed to accommodate the filter device and then used for further molecular analysis. Quantification of the collected nucleic acids may then be used in the diagnosis and/or treatment of IBD.
    Type: Application
    Filed: November 12, 2015
    Publication date: November 23, 2017
    Inventors: Satish P. RamachandraRao, Ravindra Lall Mehta, Masato Mitsuhashi, Taku Murakami
  • Publication number: 20170283789
    Abstract: The present disclosure relates to methods of collecting cervical-vaginal fluid exosomes and microvesicles and isolating corresponding mRNA. In particular, certain embodiments relate to the method of collecting the cervical-vaginal fluids with a tampon and releasing the cells, exosomes and microvesicles using excess buffer and a syringe or syringe-like device. The resulting expunged fluid can be applied to a filter device that is capable of capturing exosomes and microvesicles. Nucleic acids such as mRNA can be isolated from the cervical-vaginal fluid exosome and microvesicles using an oligo(dT)-coated plate designed to accommodate the filter device and then used for further molecular analysis. Quantification of the collected nucleic acids may then be used in the diagnosis and/or treatment of gynecological diseases or conditions.
    Type: Application
    Filed: August 27, 2015
    Publication date: October 5, 2017
    Inventors: Cindy M. Yamamoto, Vivian Tovar, Taku Murakami, Mieko Ogura, Melanie Oakes, Masato Mitsuhashi
  • Publication number: 20170247744
    Abstract: Provided herein are devices and methods for the capture or isolation of a biomarker from a biological sample. In several embodiments, the device comprises a loading region, a filter material, and a receiving region. In particular, in several embodiments, biological fluid is passed from the loading region through the filter material and into the receiving region, thereby resulting in capture or isolation of a biomarker.
    Type: Application
    Filed: March 10, 2017
    Publication date: August 31, 2017
    Inventors: Masato Mitsuhashi, Taku Murakami
  • Publication number: 20170184575
    Abstract: Methods of screening for expression of an RNA associated with a post-kidney transplant complication include collecting vesicles from urine, isolating vesicle-associated RNA, and analyzing expression patterns. In particular, AIF1, BTN3A3, CCL5, CD48, HAVCR1, or SLC6A6 mRNA expression patterns are analyzed.
    Type: Application
    Filed: March 8, 2017
    Publication date: June 29, 2017
    Inventors: Taku Murakami, Cindy Yamamoto, Masato Mitsuhashi, Hiroshi Harada
  • Patent number: 8916351
    Abstract: A method of amplifying a nucleic acid includes combining a first linear primer with a polymerase and a circular probe. The circular probe contains at least one antisense sequence to a second nucleic acid sequence and at least one antisense sequence to the first linear primer. The method also includes producing at least one repeat of an antisense copy of the circular probe by rolling circle amplification. The antisense copy contains at least the second nucleic acid sequence. The method further includes generating more than one second linear primers from each copy of the second nucleic acid sequence; and hybridizing the second linear primers to more than one of the circular probes. A ribbon probe includes a circular probe and a lock probe. The lock probe contains at least a cleavable linker, and the circular probe and the lock probe are unable to dissociate without cleaving the cleavable linker.
    Type: Grant
    Filed: January 4, 2006
    Date of Patent: December 23, 2014
    Assignees: Hitachi Chemical Co., Ltd., Hitachi Chemical Research Center, Inc.
    Inventor: Taku Murakami
  • Publication number: 20130226032
    Abstract: Disclosed are methods, device kits, and systems for improved quantification of mRNA from whole blood. More particularly, the devices and kites related thereto are useful for the controlled and repeatable ex vivo stimulation of whole blood.
    Type: Application
    Filed: October 31, 2011
    Publication date: August 29, 2013
    Applicants: HITACHI CHEMICAL RESEARCH CENTER, INC., HITACHI CHEMICAL COMPANY, LTD.
    Inventors: Masato Mitsuhashi, Taku Murakami